NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.20+₹41.20 (+2.34%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · SUVEN.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Suven Life Sciences Limited’s quoted price sits in the lower half of its reported 52-week range, 35.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Suven Life Sciences Limited’s forward annual dividend is ₹1.38 per share, paid annual. The forward yield is 0.53% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Suven Life Sciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₹25.73M-99.79% vs estimate |
| Q1 2025 | Aug 5, 2024 | -₹1.29 | ₹10.06B-19.54% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.20+₹41.20 (+2.34%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹1,355.40+₹10.40 (+0.77%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
₹1,376.40+₹18.40 (+1.35%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.61% below the high.
₹2,008.50+₹18.60 (+0.93%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.6% below the high.
₹2,312.30-₹26.70 (-1.14%)
Glenmark Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 8.88% below the high.
₹1,866.60+₹1.60 (+0.09%)
Emcure Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.14% below the high.
₹783.70-₹3.85 (-0.49%)
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 36.12% below the high.
₹176.80-₹6.18 (-3.38%)
Sun Pharma Advanced Research Company Limited’s quoted price sits in the lower half of its reported 52-week range, 38.82% below the high.
